Released on: May 28, 2008, 5:23 am

Press Release Author: The Scott Partnership

Industry:

Press Release Summary: (May 28, 2008) Biotage, a leading supplier of tools and
technology for medicinal and analytical chemistry, announces the introduction of the
new Isolera compact FLASH purification system. This unique new instrument enables
chemists to easily achieve better separations in significantly shorter purification
run-times, while new features result in maximum purity and yield.

Press Release Body: News release
Contact:
Jennifer Whedbee, Director Marketing Communications
Tel: +1 434 220 2652, jwhedbee@biotage.com

Biotage Introduces New Isolera FLASH Purification System for Faster Separations

(May 28, 2008) Biotage, a leading supplier of tools and technology for medicinal and
analytical chemistry, announces the introduction of the new Isolera compact FLASH
purification system. This unique new instrument enables chemists to easily achieve
better separations in significantly shorter purification run-times, while new
features result in maximum purity and yield.

The high-performance Isolera system from Biotage contains intelligent features which
allow users to maximize time and resources. The advanced TLC-to-gradient feature
automatically creates elution gradients and suggests cartridge and sample size.
Compounds can be collected on two separate wavelengths using a variable wavelength
detector option, resulting in increased compound recovery and cleaner fractions.

With the Isolera FLASH purification system, up to four solvents can be used in a
single gradient to easily purify samples with diverse polarity. A third co-solvent
can be isocratically pumped into the binary gradient, maintaining compound
solubility and eliminating the over-pressure issues that can be caused by
precipitating compounds. Users have full control over sample purification
conditions, as a full range of editing options is available, including gradient,
flow rate, collection volume and fraction wavelengths and modes.

Providing default methods built around both TLC conditions and SNAP cartridge sizes,
the new Isolera system enables chemists to quickly purify samples. Samples with poor
or no UV chromophore can be purified by connecting an external detector such as
refractive index or evaporative light scattering detector (ELSD) to the system.
Isolera fractionates compounds using the auxiliary detector\'s signal while
simultaneously monitoring the Isolera UV signal.

The Isolera system from Biotage comes complete with SNAP cartridges and everything
required to begin purifying samples quickly.

For more information on the Isolera FLASH purification system, please call
434-979-2319 (press 3), email product_info@biotage.com, or visit www.biotage.com

-ENDS-
For further press information please contact: Eleanor CallanMonk, The Scott
Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA Tel:
+44 1477 539539 Fax: +44 1477 539540 e-mail: biotage@scottpr.com

About Biotage
Biotage is a global company active in life science research with strong
technologies, a broad range of operations and a long-term view of the market. The
company offers solutions, knowledge and experience in the areas of genetic analysis
and medicinal chemistry. In 2005 operations and products were acquired from the
American company Argonaut, further strengthening the medicinal chemistry product
range. The customers include the world\'s top 30 pharmaceutical companies, the
world\'s top 20 biotech companies, and leading academic institutes. The company is
headquartered in Uppsala and has offices in the U.S., Japan, UK, Germany and several
other European countries.
Biotage has 336 employees and had sales of 496,4 MSEK in 2007. Biotage is listed on
the OMX Nordic Exchange Stockholm AB. Website: www.biotage.com

Certain statements in this press release are forward-looking. These may be
identified by the use of forward-looking words or phrases such as \"believe,\"
\"expect,\" \"intend,\" and \"should,\" among others. These forward-looking statements are
based on Biotage\'s current expectations. The Private Securities Litigation Reform
Act of 1995 provides a \"safe harbor\" for such forward-looking statements. In order
to comply with the terms of the safe harbor, Biotage notes that a variety of factors
could cause actual results and experience to differ materially from the anticipated
results or other expectations expressed in such forward-looking statements. Such
uncertainties and risks include, but are not limited to, risks associated with
management of growth and international operations (including the effects of currency
fluctuations), variability of operating results, the commercial development of the
microwave synthesis and flash purification in the drug discovery market, DNA
sequencing and genomics market, nucleic acid-based molecular diagnostics market, and
genetic vaccination and gene therapy markets, competition, rapid or unexpected
changes in technologies, fluctuations in demand for Biotage\'s products (including
seasonal fluctuations), difficulties in successfully adapting the Company\'s products
to integrated solutions and producing such products, and the Company\'s ability to
identify and develop new products and to differentiate its products from
competitors.


Web Site: http://

Contact Details: Eleanor CallanMonk, The Scott Partnership, 1 Whiteside, Station
Road, Holmes Chapel, Cheshire CW4 8AA Tel:
+44 1477 539539 Fax: +44 1477 539540 e-mail: biotage@scottpr.com